- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06649058
EXCLAMA: Exploración de enfoques locales y sistémicos combinados en metástasis cerebrales: un estudio de fase II aleatorizado de cohortes múltiples que evalúa la respuesta inicial a la terapia sistémica y la integración posterior de la radiocirugía estereotáxica en pacientes con metástasis cerebrales de bajo riesgo y sistema nervioso central activo
EXCLAMA: Exploración de enfoques locales y sistémicos combinados en metástasis cerebrales: un estudio de fase II aleatorizado de cohortes múltiples que evalúa la respuesta inicial a la terapia sistémica y la integración posterior de la radiocirugía estereotáxica en pacientes con metástasis cerebrales de bajo riesgo y opciones de terapia sistémica activa en el sistema nervioso central
To learn if consolidative stereotactic radiosurgery (cSRS) can help to control central nervous system (CNS) disease in patients who have brain metastases and have a partial response or stable brain metastases after systemic therapy.
To learn if using SRS to treat all brain metastases that do not respond to systemic therapy versus treating only metastases that are getting worse can help to control CNS disease in patients whose disease gets worse after systemic therapy.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Primary Objectives:
To assess whether cSRS improves CNS progression-free survival (CNS-PFS) in patients with BM who have a PR or SD with upfront systemic therapy.
To assess whether SRS to all BM not in CR (cSRS + pdSRS) versus only progressing lesions (pdSRS) improves CNS-PFS in patients with CNS progression on upfront systemic therapy.
Secondary Objectives:
To report the rate and degree of response of BM to systemic therapy by specific regimen and histology.
To report adverse neurologic events that occur with BM treated with upfront systemic therapy and differences in these events between various downstream radiation therapy options (omission, cSRS, pdSRS, etc).
To evaluate rates of LMD in all patients managed with upfront systemic therapy and differences in LMD rates between various downstream radiation therapy options (omission, cSRS, pdSRS, etc).
To evaluate neurocognitive changes in patients treated with upfront systemic therapy for BMand differences in these changes between various downstream radiation therapy options (omission, cSRS, pdSRS, etc).
To perform inference on overall survival as estimated by the Kaplan-Meier estimator in patients treated with upfront systemic therapy for BM and differences in these changes between various downstream radiation therapy options (omission, cSRS, pdSRS, etc).
Exploratory Objectives:
To correlate imaging biomarkers with outcomes of BM treated with systemic therapy.
To correlate volumetric assessment of lesion response to conventional assessment by mRECIST 1.1.
To explore ML as a tool to predict outcomes of BM treatment based on disease specific, clinical, and lesion specific features.
To explore the association of circulating bioanalytes with up front systemic therapy for BM and subsequent downstream management strategies (i.e. cSRS).
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Thomas H Bekham, MD,PHD
- Número de teléfono: 713-825-3169
- Correo electrónico: thbeckham@mdanderson.org
Ubicaciones de estudio
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- The University of Texas MD Anderson Cancer Center
-
Contacto:
- Thomas H Beckham, MD,PHD
- Número de teléfono: 713-825-3169
- Correo electrónico: thbeckham@mdanderson.org
-
Investigador principal:
- Thomas H Beckham, MD,PHD
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age ≥ 18 years.
- Evaluation by a brain metastasis multidisciplinary team (BM-MDT) consisting of a medical oncologist (can be the patient's primary medical oncologist), a radiation oncologist who regularly performs SRS, and a neurosurgeon. This evaluation can take place in clinic or during a multidisciplinary conference.
- Life expectancy > 6 months as estimated by BM-MDT.
- BM-MDT agreement that the planned systemic therapy regimen may provide intracranial benefit (SD, PR, or CR in the CNS).
- BM-MDT agreement that the patient's BM does not require immediate local therapy (surgery and/or radiation therapy); i.e. it is judged to be safe to omit local therapy as initial BM management.
- The patient's BM are amenable to SRS as initial local therapy as determined by BM-MDT.
- Subjects must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol-related procedures that are not part of normal subject care.
- Histologically confirmed metastatic cancer with at least one measurable metastasis in the brain (≥ 5 mm).
- At least one measurable intracranial target lesion which was not previously treated with SRS. Regrowth in a cavity of previously excised lesion will not qualify as a measurable lesion. Growth or change in a lesion previously irradiated will not qualify as a measurable lesion.
- Prior SRS and prior excision of BM is permitted if other measurable non irradiated lesions as described in #9 remain.
- The resection cavity of excised BM must have received appropriate radiation therapy (pre or post operative SRS, brachytherapy) or have been observed for >6 months after resection without evidence of local cavity recurrence.
- Subjects must be free of neurologic signs and symptoms related to metastatic brain lesions either without systemic corticosteroids or requiring ≤ 2 mg dexamethasone daily for symptom resolution.
- ECOG performance status ≤ 1.
- Documented agreement by the patient's primary medical oncologist with the appropriateness of planned SST regimen.
- This study will allow non-English speaking subjects to be enrolled. Verbal Translation Preparative Sheet (VTPS) will be used if a translated consent form is not available in the subject's language. The consent form will be translated into the language of the subject after 2 or more occurrences. This will apply to any MD Anderson patient.
Exclusion Criteria:
- History of known leptomeningeal involvement (radiographic or cytological).
- Small cell lung cancer, lymphoma, or leukemia histology.
- Non-small cell lung cancer histology with targetable oncogenic driver mutation with planned initiation of highly CNS active targeted therapy (eg osimertinib, brigatinib, alectinib, or lorlatinib).
- Subjects previously treated with WBRT.
- Any intact BM size > 3 cm. After surgical excision and appropriate radiation therapy to the cavity, patients may enroll if additional eligible lesions are present.
- Prior disease progression on one or more of the agents comprising SST.
- Exposure to one or more agents comprising SST within the last 30 days.
- Prior unacceptable toxicity during treatment with one or more agents comprising SST.
- Subjects with a major medical, neurologic or psychiatric condition who are judged as unable to fully comply with study therapy or assessments should not be enrolled.
- History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. Note: The time requirement does not apply to participants who underwent successful treatment of superficial bladder cancer, in situ cervical cancer, ductal carcinoma in situ, or other in-situ cancers. Subjects with a completely treated prior malignancy and no evidence of disease for ≥ 2 years are eligible.
- Skin Cancer Exclusion: Please note that localized cutaneous basal cell carcinoma and squamous cell carcinoma is not an exclusion criterion regardless of treatment status. Biopsy proven metastatic disease from these histologies is an exclusion criterion if this constitutes a second cancer.
- Patient weight >450 pounds.
- Patient had prior SRS to any intracranial lesion <15mm from a metastasis on the screening MRI. Prior MRIs and DICOMs will be used to make this determination.
- Patient unable to receive a brain MRI (implanted metal devices or foreign bodies) or MRI contrast.
- Any BM with a significant hemorrhagic component (defined as MRI T1 intrinsic hyperintensity comprising ≥ 25% of maximal lesion diameter).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: cSRS PR or SD
Patients with a CR will be observed with ongoing standard of care MRI. Patients with SD or PR will be randomized to receive cSRS or ongoing observation. |
Participants will receive systemic therapy as a standard of care therapeutic option Participants will receive systemic therapy as a standard of care therapeutic option |
|
Experimental: a-pdSR CNS PD
At the time of CNS PD, patients will also be randomized to pdSRS versus pdSRS + cSRS. |
Participants will receive systemic therapy as a standard of care therapeutic option Participants will receive systemic therapy as a standard of care therapeutic option |
|
Experimental: b-PDC CNS PD
At the time of CNS PD, patients will also be randomized to pdSRS versus pdSRS + cSRS. |
Participants will receive systemic therapy as a standard of care therapeutic option Participants will receive systemic therapy as a standard of care therapeutic option |
|
Experimental: SST treated SD or PR patients to receive cSRS/ ongoing observation
Patients with a CR will be observed with ongoing standard of care MRI. Patients with SD or PR will be randomized to receive cSRS or ongoing observation. |
Participants will receive systemic therapy as a standard of care therapeutic option Participants will receive systemic therapy as a standard of care therapeutic option |
|
Experimental: SST treated PD patients to pdSRS / pdSRS+cSRS
At the time of CNS PD, patients will also be randomized to pdSRS versus pdSRS + cSRS. |
Participants will receive systemic therapy as a standard of care therapeutic option Participants will receive systemic therapy as a standard of care therapeutic option |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Safety and Adverse Events (AEs).
Periodo de tiempo: Through study completion; an average of 1 year.
|
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 |
Through study completion; an average of 1 year.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Thomas H Beckham, MD,PHD, M.D. Anderson Cancer Center
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Neoplasias por sitio
- Neoplasias
- Neoplasias del Sistema Nervioso
- Neoplasias del Sistema Nervioso Central
- Neoplasias Cerebrales
- Técnicas de investigación
- Terapéutica
- Procedimientos quirúrgicos, operativo
- Radioterapia
- Técnicas estereotáxicas
- Procedimientos neurociruúrgicos
- Radiocirugía
Otros números de identificación del estudio
- 2024-1383
- NCI-2024-08780 (Otro identificador: NCI-CTRP Clinical Trials Registry)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .